Evidence map›Paper›PMID 36754883›Full record

ReviewAMB Express2023

The gut microbiota pathway mechanisms of diabetes.

Ousman Bajinka, Yurong Tan, Alansana Darboe, Isabella Gloria Ighaede-Edwards, Khalid A Abdelhalim

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in AMB Express, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Epidemiology of small intestinal bacterial overgrowth.World journal of gastroenterology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Ousman BajinkaDepartment of Medical Microbiology, Xiangya School of Medicine, Central South University, Changsha, 410078, Hunan, China.
Yurong TanDepartment of Medical Microbiology, Xiangya School of Medicine, Central South University, Changsha, 410078, Hunan, China. yurongtan@csu.edu.cn.ORCID http://orcid.org/0000-0002-2871-4078
Alansana DarboeVaccine & Immunity Theme, Infant Immunology, Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine (MRCG@LSHTM), Fajara, Gambia.
Isabella Gloria Ighaede-EdwardsDepartment of Maternal and Child Health, Xiangya School of Public Health, Central South University, Changsha, Hunan, China.
Khalid A AbdelhalimIzmir Biomedicine and Genome Center, Izmir, Turkey.
Central South University · CNIzmir University · TRMRC Unit the Gambia · GM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The contribution of dysbiotic gut microbiota configuration is essential when making reference to the metabolic disorders by increasing energy. It is important to understand that the gut microbiota induced metabolic disease mechanisms and inflammations. Thus it is imperative to have an insight into the state of all chronic subclinical inflammations influencing disease outcomes. However, from the emerging studies, there still exist inconsistencies in the findings of such studies. While making the best out of the reasons for inconsistencies of the findings, this review is designed to make a clear spell out as to the inconsistence of gut microbiota with respect to diabetes. It considered gut-virome alterations and diabetes and gut-bacteriome-gut-virome-alterations and diabetes as confounding factors. The review further explained some study design strategies that will spontaneously eliminate any potential confounding factors to lead to a more evidence based diabetic-gut microbiota medicine. Lipopolysaccharide (LPS) pro-inflammatory, metabolic endotoxemia and diet/gut microbiota insulin-resistance and low-grade systemic inflammation induced by gut microbiota can trigger pro-inflammatory cytokines in insulin-resistance, consequently, leading to the diabetic condition. While diet influences the gut microbiota, the consequences are mainly the constant high levels of pro-inflammatory cytokines in the circulatory system. Of recent, dietary natural products have been shown to be anti-diabetic. The effects of resveratrol on the gut showed an improved lipid profile, anti-inflammatory properties and ameliorated the endotoxemia, tight junction and glucose intolerance.

Indexed as

DiabetesGut-bacteriome–gut-virome-alterationsGut microbiotaGut-virome alterationsInconsistencies

Identifiers

PMID36754883
PMCPMC9908804
OpenAlexW4319590382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.